J&J’s Booster Offers Strong Protection Against Hospitalization

By PacConAdmin | December 30, 2021

Two doses of the Johnson & Johnson (J&J) COVID-19 vaccine (Ad26.COV2.S) cut the risk of a COVID-related hospitalization by 85 percent, the company has reported — and the benefit may be coming from ramped-up T-cells rather than vaccine-induced antibodies.
Source: Drug Industry Daily

Posted in Drug Industry Daily